NeurAxis (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for children and adults, announced its financial and operational results for the fourth quarter and full fiscal year ended December 31, 2025.
Aveanna Healthcare Holdings (NASDAQ:AVAH) announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, reporting a period of accelerated growth and significant margin expansion.
Eli Lilly and Company (NYSE:LLY) today announced positive topline results from TRANSCEND-T2D-1, the first Phase 3 clinical trial evaluating retatrutide for the treatment of type 2 diabetes.
DarioHealth (NASDAQ:DRIO) today announced its financial results for the fourth quarter and full year ended December 31, 2025, describing the period as a critical "foundation-building" year.
Evotec (NASDAQ:EVO) announced today that it will receive a $10 million milestone payment from Bristol Myers Squibb (NYSE:BMY) following the start of a Phase 1 clinical trial for BMS-986506.
KYO Pharma (NASDAQ:OKYO) reported new exploratory Phase 2a findings for its lead candidate, urcosimod (0.05%), demonstrating that the topical therapy significantly improves the quality of life (QoL) for patients suffering from neuropathic corneal pain (NCP).
Aclaris Therapeutics (NASDAQ:ACRS) announced it has successfully completed patient enrollment for its Phase 2 clinical trial of bosakitug (ATI-045), an investigational treatment for patients suffering from moderate-to-severe atopic dermatitis.
Ovid Therapeutics (NASDAQ:IVID) announced a $60 million private placement to fund the expansion of its clinical pipeline into tuberous sclerosis complex seizures and infantile spasms.
Dogwood Therapeutics (NASDAQ:DWTX) reported its fourth-quarter and full-year 2025 financial results, highlighting a pivot toward late-stage clinical development for its lead analgesic candidate, Halneuron®.
Cingulate (NASDAQ:CING) announced its fourth-quarter and full-year 2025 financial results alongside several critical regulatory milestones on March 18, 2026.
InspireMD (NASDAQ:NSPR) reported a significant acceleration in its commercial operations for the fourth quarter of 2025, fueled by the successful U.S. market introduction of its CGuard Prime Carotid Stent System.
Biotech royalty aggregator XOMA Royalty 9NASDAQ:XOMA) reported a sharp financial turnaround for its 2025 fiscal year, swinging to a robust profit on the back of surging revenues and executing multiple shareholder-value initiatives.
